Which of the following conditions are treated with anti‑TNF biologic agents that inhibit tumor necrosis factor‑alpha (TNF‑α) activity?

Anti-TNF Biologic Agents: Approved Indications

Anti-TNF biologic agents are used to treat psoriasis (a), rheumatoid arthritis (b), ulcerative colitis (d), and ankylosing spondylitis (e), but NOT systemic lupus erythematosus (SLE). The correct answers are a, b, d, and e.

Established Indications

Based on comprehensive guideline evidence, anti-TNF agents have been approved for the following conditions 1:

Confirmed Indications:

• Rheumatoid arthritis (RA) - All five TNF inhibitors (infliximab, adalimumab, certolizumab pegol, etanercept, golimumab) are highly effective 1

• Ankylosing spondylitis - All anti-TNF agents demonstrate very effective outcomes 1

• Psoriasis - Approved indication with proven efficacy 1, 2

• Psoriatic arthritis (PsA) - Established treatment option 1

• Ulcerative colitis (UC) - Specifically infliximab, adalimumab, and golimumab can induce clinical and endoscopic remission 1, 3

• Crohn's disease - Multiple anti-TNF agents approved 1, 3

Critical Distinction for Ulcerative Colitis:

Not all anti-TNF agents work equally in inflammatory bowel disease. Etanercept (the soluble TNF receptor fusion protein) is NOT effective for ulcerative colitis or Crohn's disease, unlike the monoclonal antibodies (infliximab, adalimumab, golimumab) 1. This represents an important clinical pitfall when selecting therapy.

SLE: A Contraindication

Systemic lupus erythematosus (SLE) is NOT treated with anti-TNF agents. In fact, TNF inhibitors can paradoxically induce lupus-like syndromes and are generally avoided in SLE patients. The pathophysiology of SLE differs fundamentally from the TNF-driven inflammatory conditions listed above.

Additional Approved Indications

Beyond the options listed in your question, anti-TNF agents are also approved for 1:

• Juvenile idiopathic arthritis
• Behçet's disease
• Uveitis (in pediatric and adult patients)

Clinical Algorithm

When considering anti-TNF therapy:

1. Confirm the diagnosis - Ensure it's one of the TNF-driven inflammatory conditions (RA, SpA, PsA, psoriasis, IBD)

2. Select the appropriate agent:

   • For IBD (UC/Crohn's): Use infliximab, adalimumab, or golimumab - avoid etanercept
   • For rheumatic diseases: Any of the five agents are effective
   • For psoriasis: All agents approved, though infliximab shows rapid response 2

3. Exclude SLE - Do not use anti-TNF agents in lupus patients

The evidence consistently demonstrates that anti-TNF biologics have revolutionized treatment across multiple inflammatory conditions by targeting the TNF-α pathway, which is central to disease pathogenesis in these specific disorders 1, 4, 5.